MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics

Jyotika Varshney, Subree Subramanian

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Sarcomas are highly aggressive heterogeneous tumors that are mesenchymal in origin. There have been vast advancements on identifying diagnostic markers for sarcomas including chromosomal translocations, but very little progress has been made to identify targeted therapies against them. The tumor heterogeneity, genetic complexity and the lack of drug studies make it challenging to recognize the potential targets and also accounts for the inadequate treatments in sarcomas. In recent years, microRNAs that are a part of small non-coding RNAs have shown promising results as potential diagnostic and prognostic biomarkers in multiple sarcoma types. This review focuses on the current knowledge of the microRNAs that are deregulated in sarcomas, and an insight on the strategies to target these microRNAs that are essential for developing improved therapies for various human sarcomas.

Original languageEnglish (US)
Article number31
JournalFrontiers in Molecular Biosciences
Volume2
Issue numberJUN
DOIs
StatePublished - Jun 17 2015

Fingerprint

MicroRNAs
Sarcoma
Bone
Tissue
Bone and Bones
Tumors
Small Untranslated RNA
Biomarkers
Therapeutics
Genetic Translocation
Genetic Heterogeneity
Pharmaceutical Preparations
Neoplasms

Keywords

  • Bone sarcoma
  • MicroRNAs
  • Osteosarcoma
  • Pediatric oncology
  • Sarcoma
  • Soft tissue sarcoma
  • Therapeutics

Cite this

MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics. / Varshney, Jyotika; Subramanian, Subree.

In: Frontiers in Molecular Biosciences, Vol. 2, No. JUN, 31, 17.06.2015.

Research output: Contribution to journalReview article

@article{d78fce03c73c4f54baf64088fccfb62a,
title = "MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics",
abstract = "Sarcomas are highly aggressive heterogeneous tumors that are mesenchymal in origin. There have been vast advancements on identifying diagnostic markers for sarcomas including chromosomal translocations, but very little progress has been made to identify targeted therapies against them. The tumor heterogeneity, genetic complexity and the lack of drug studies make it challenging to recognize the potential targets and also accounts for the inadequate treatments in sarcomas. In recent years, microRNAs that are a part of small non-coding RNAs have shown promising results as potential diagnostic and prognostic biomarkers in multiple sarcoma types. This review focuses on the current knowledge of the microRNAs that are deregulated in sarcomas, and an insight on the strategies to target these microRNAs that are essential for developing improved therapies for various human sarcomas.",
keywords = "Bone sarcoma, MicroRNAs, Osteosarcoma, Pediatric oncology, Sarcoma, Soft tissue sarcoma, Therapeutics",
author = "Jyotika Varshney and Subree Subramanian",
year = "2015",
month = "6",
day = "17",
doi = "10.3389/fmolb.2015.00031",
language = "English (US)",
volume = "2",
journal = "Frontiers in Molecular Biosciences",
issn = "2296-889X",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics

AU - Varshney, Jyotika

AU - Subramanian, Subree

PY - 2015/6/17

Y1 - 2015/6/17

N2 - Sarcomas are highly aggressive heterogeneous tumors that are mesenchymal in origin. There have been vast advancements on identifying diagnostic markers for sarcomas including chromosomal translocations, but very little progress has been made to identify targeted therapies against them. The tumor heterogeneity, genetic complexity and the lack of drug studies make it challenging to recognize the potential targets and also accounts for the inadequate treatments in sarcomas. In recent years, microRNAs that are a part of small non-coding RNAs have shown promising results as potential diagnostic and prognostic biomarkers in multiple sarcoma types. This review focuses on the current knowledge of the microRNAs that are deregulated in sarcomas, and an insight on the strategies to target these microRNAs that are essential for developing improved therapies for various human sarcomas.

AB - Sarcomas are highly aggressive heterogeneous tumors that are mesenchymal in origin. There have been vast advancements on identifying diagnostic markers for sarcomas including chromosomal translocations, but very little progress has been made to identify targeted therapies against them. The tumor heterogeneity, genetic complexity and the lack of drug studies make it challenging to recognize the potential targets and also accounts for the inadequate treatments in sarcomas. In recent years, microRNAs that are a part of small non-coding RNAs have shown promising results as potential diagnostic and prognostic biomarkers in multiple sarcoma types. This review focuses on the current knowledge of the microRNAs that are deregulated in sarcomas, and an insight on the strategies to target these microRNAs that are essential for developing improved therapies for various human sarcomas.

KW - Bone sarcoma

KW - MicroRNAs

KW - Osteosarcoma

KW - Pediatric oncology

KW - Sarcoma

KW - Soft tissue sarcoma

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84944149792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944149792&partnerID=8YFLogxK

U2 - 10.3389/fmolb.2015.00031

DO - 10.3389/fmolb.2015.00031

M3 - Review article

VL - 2

JO - Frontiers in Molecular Biosciences

JF - Frontiers in Molecular Biosciences

SN - 2296-889X

IS - JUN

M1 - 31

ER -